Chimeric antigen receptor therapy for cancer.
暂无分享,去创建一个
David L Porter | S. Grupp | D. Porter | C. June | D. Barrett | Stephan A Grupp | Carl H June | Nathan Singh | David M Barrett | Nathan Singh
[1] Hong Qian,et al. Statistics and Related Topics in Single-Molecule Biophysics. , 2014, Annual review of statistics and its application.
[2] Christina D Smolke,et al. Synthetic biology: advancing biological frontiers by building synthetic systems , 2012, Genome Biology.
[3] S. Riddell,et al. NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[4] J. Shaw,et al. Augmentation of post transplant immunity: antigen encounter at the time of hematopoietic stem cell transplantation enhances antigen-specific donor T-cell responses in the post transplant repertoire , 2005, Bone Marrow Transplantation.
[5] D. Powell,et al. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. , 2012, Blood.
[6] F. Marincola,et al. A human memory T-cell subset with stem cell-like properties , 2011, Nature Medicine.
[7] R. Storb,et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.
[8] Bruce R. Blazar,et al. Engineering lymphocyte subsets: tools, trials and tribulations , 2009, Nature Reviews Immunology.
[9] S. Sleijfer,et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] David H. Chong,et al. New cost-effective treatment strategies for acute emergency situations. , 2014, Annual review of medicine.
[11] F. Gage,et al. In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.
[12] M. Tan,et al. Rapid Immune Recovery and Graft-versus-Host Disease–like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells , 2009, Clinical Cancer Research.
[13] Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. , 1986, Blood.
[14] David L. Porter,et al. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.
[15] A. Theofilopoulos,et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. , 2002, The Journal of clinical investigation.
[16] M. Sadelain,et al. Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes , 1998, The Journal of experimental medicine.
[17] Jing Sun,et al. Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor , 2011, Clinical Cancer Research.
[18] S. Grupp,et al. Treatment of advanced leukemia in mice with mRNA engineered T cells. , 2011, Human gene therapy.
[19] Gang Wang,et al. A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.
[20] S. Rosenberg,et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] R. Weissleder,et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo , 2005 .
[22] Adrian P Gee,et al. Inducible apoptosis as a safety switch for adoptive cell therapy. , 2011, The New England journal of medicine.
[23] H. Heslop,et al. Adoptive cellular immunotherapy for EBV lymphoproliferative diseases , 1997 .
[24] J. Loutit,et al. Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow , 1956, British medical journal.
[25] Melvin Cohn,et al. A Theory of Self-Nonself Discrimination , 1970, Science.
[26] W. Wilson,et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.
[27] E. Estey,et al. A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. , 2009, Immunity.
[28] Hao Liu,et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. , 2011, The Journal of clinical investigation.
[29] F. Bushman,et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. , 2008, The Journal of clinical investigation.
[30] G. Mathé,et al. Adoptive immunotherapy of acute leukemia: experimental and clinical results. , 1965, Cancer research.
[31] D. Scadden,et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. , 2000, Blood.
[32] Michel Sadelain,et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.
[33] E. Basch. New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment. , 2014, Annual review of medicine.
[34] G. Schuler,et al. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer , 2009, Gene Therapy.
[35] Miller Ad,et al. Improved Retroviral Vectors for Gene Transfer and Expression , 1989 .
[36] Mike Gough,et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.
[37] D. Campana,et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia , 2004, Leukemia.
[38] S. Weissman,et al. Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes. , 2008, Human gene therapy.
[39] G. Dranoff,et al. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation. , 2002, Cancer research.
[40] J. Loutit,et al. Treatment of Murine Leukaemia with X‐Rays and Homologous Bone Marrow: II , 1957, British journal of haematology.
[41] S. Rosenberg,et al. Passive immunotherapy of cancer in animals and man. , 1977, Advances in cancer research.
[42] E. Shpall,et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. , 2012, Human gene therapy.
[43] G. Dotti,et al. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. , 2010, Blood.
[44] Donna Niedzwiecki,et al. Telomerase mRNA-Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate Cancer 1 , 2005, The Journal of Immunology.
[45] Gunnar Kvalheim,et al. Transiently redirected T cells for adoptive transfer. , 2011, Cytotherapy.
[46] F. Raal,et al. Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. , 2014, Annual review of medicine.
[47] N. A. MITCttlSON. STUDIES ON THE IMMUNOLOGICAL RESPONSE TO FOREIGN TUMOR TRANSPLANTS IN THE MOUSE , 2003 .
[48] S. Yoon,et al. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model , 2009, Cancer Gene Therapy.
[49] S. Riddell,et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. , 2009, Blood.
[50] S. Shurtleff,et al. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[51] S. Rosenberg,et al. Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy1 , 2005, The Journal of Immunology.
[52] G. Plautz,et al. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells. , 2005, Cancer research.
[53] J. Thompson,et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[54] A. Jawad,et al. Adoptive Transfer of Autologous T Cells Improves T-cell Repertoire Diversity and Long-term B-cell Function in Pediatric Patients with Neuroblastoma , 2012, Clinical Cancer Research.
[55] B. Levine,et al. Regulated expression of telomerase activity in human T lymphocyte development and activation , 1996, The Journal of experimental medicine.
[56] K. Harjai,et al. Transcatheter aortic valve replacement: game-changing innovation for patients with aortic stenosis. , 2014, Annual review of medicine.
[57] J. Berzofsky,et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells , 2005, Nature Medicine.
[58] Yun Ji,et al. Adoptively transferred effector cells derived from naïve rather than central memory CD8+ T cells mediate superior antitumor immunity , 2009, Proceedings of the National Academy of Sciences.
[59] M. Raffeld,et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.
[60] C. June,et al. The Inducible Costimulator (ICOS) Is Critical for the Development of Human TH17 Cells , 2010, Science Translational Medicine.
[61] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[62] C. E. Ford,et al. Tissue transplantation in the radiation chimera. , 1957, Journal of cellular physiology. Supplement.
[63] W. Wilson,et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.
[64] M. Connors,et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. , 1997, Journal of immunology.
[65] C. Nemeroff,et al. Depression as a risk factor for cancer: from pathophysiological advances to treatment implications. , 2014, Annual review of medicine.
[66] Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. , 2010, Cancer research.
[67] F. Bushman,et al. Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells , 2012, Science Translational Medicine.
[68] A. Lawson,et al. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. , 1998, Journal of immunology.
[69] S. Grupp,et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. , 2003, Blood.
[70] M. Tan,et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. , 2011, Blood.
[71] B. Levine,et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. , 2010, Cancer research.
[72] M. Sadelain,et al. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. , 2011, Cancer research.
[73] Egbert Oosterwijk,et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. , 2011, Blood.
[74] B. Coiffier,et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus , 2010, British journal of haematology.
[75] F. Marincola,et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. , 2011, The Journal of clinical investigation.
[76] A. Lawson,et al. Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ Chain , 2004, The Journal of Immunology.
[77] C. June,et al. Extensive Replicative Capacity of Human Central Memory T Cells1 , 2004, The Journal of Immunology.
[78] B. Nelson,et al. Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[79] M. Roederer,et al. T-cell quality in memory and protection: implications for vaccine design , 2008, Nature Reviews Immunology.
[80] Alexander Perl,et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. , 2006, Blood.
[81] Martin Pule,et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. , 2011, Blood.
[82] Z. Eshhar,et al. Functional expression of chimeric receptor genes in human T cells. , 2001, Journal of immunological methods.
[83] M. Slovak,et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[84] M. Brenner,et al. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells , 2006, Leukemia.
[85] C. June,et al. 4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy1 , 2007, The Journal of Immunology.
[86] S. Rosenberg,et al. Bcl-2 overexpression enhances tumor-specific T-cell survival. , 2005, Cancer research.
[87] C. Klebanoff,et al. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. , 2005, Trends in immunology.
[88] T. Brocker. Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in peripheral T cells , 2000 .
[89] Herbert Pardes,et al. Delivering value: provider efforts to improve the quality and reduce the cost of health care. , 2014, Annual review of medicine.
[90] M. Barnes,et al. Gene-expression signatures differ between different clinical forms of familial hemophagocytic lymphohistiocytosis. , 2013, Blood.
[91] Jinjuan Wang,et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. , 2012, Blood.
[92] H. Heslop,et al. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. , 1997, Immunological reviews.
[93] A. Miller,et al. Improved retroviral vectors for gene transfer and expression. , 1989, BioTechniques.
[94] M. Kalos,et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[95] C. Dunbar,et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. , 2003, Blood.
[96] T. Quinn,et al. Male circumcision: a globally relevant but under-utilized method for the prevention of HIV and other sexually transmitted infections. , 2014, Annual review of medicine.
[97] C. Macken,et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[98] P. Marrack,et al. Control of homeostasis of CD8+ memory T cells by opposing cytokines. , 2000, Science.
[99] D. Campana,et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[100] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[101] S. Rosenberg,et al. CARs on track in the clinic. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.